Targeted Antibacterial Activity Guided by Bacteria-Specific Nitroreductase Catalytic Activation to Produce...

Area of Science:

• Microbiology
• Medicinal Chemistry
• Pharmacology

Background:

• Fluoroquinolones (FQs) are critical antibiotics for Gram-negative bacterial infections.
• Toxicity concerns have led to restricted FQ use, necessitating targeted delivery strategies.
• Bacterial enzymes offer a potential mechanism for selective prodrug activation.

Purpose of the Study:

• To synthesize and evaluate a novel prodrug designed for bacteria-specific activation of ciprofloxacin (CIP).
• To demonstrate selective activation of the prodrug within bacteria, avoiding mammalian cell activation.
• To assess the in vitro and in vivo efficacy of the prodrug against Gram-negative bacteria.

Main Methods:

• Synthesis of a ciprofloxacin-latent fluorophore conjugate (1) designed as a substrate for bacterial nitroreductase (NTR).
• In vitro studies to assess NTR-mediated activation, CIP release, fluorescence generation, and bacterial killing.
• In vivo evaluation in a neutropenic mouse thigh infection model to determine bacterial burden reduction.

Main Results:

• The synthesized prodrug (1) was efficiently activated by NTR, releasing active ciprofloxacin (CIP) and a fluorescent reporter.
• Evidence of prodrug permeation and fluorescence generation within bacteria, with no observed activation in mammalian cells.
• Prodrug 1 exhibited potent bactericidal activity comparable to CIP and significantly reduced bacterial burden in vivo.

Conclusions:

• A novel prodrug strategy enables bacteria-specific delivery and activation of fluoroquinolones.
• This approach enhances antibiotic selectivity, potentially mitigating toxicity associated with conventional FQ use.
• The developed prodrug demonstrates significant therapeutic potential for treating Gram-negative bacterial infections.